Price T Rowe Associates Inc Uni Qure N.V. Call Options Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding QURE
# of Institutions
143Shares Held
34.9MCall Options Held
1.54MPut Options Held
389K-
Vestal Point Capital, LP New York, NY4.75MShares$34 Million1.59% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.65MShares$19 Million0.79% of portfolio
-
Abrdn PLC1.93MShares$13.8 Million0.02% of portfolio
-
Black Rock Inc. New York, NY1.93MShares$13.8 Million0.0% of portfolio
-
683 Capital Management, LLC New York, NY1.9MShares$13.6 Million0.78% of portfolio
About uniQure N.V.
- Ticker QURE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,729,100
- Market Cap $335M
- Description
- uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...